Numerous studies have shown that the risk of Alzheimer's disease (AD) is associated with the dose of the € 4 allele of apolipoprotein E (ApoE). However, more than one third of AD patients lack ~4 and many persons having ~4 survive cognitively intact to old age. We evaluated the lifetime risk of disease in 3,999 first-degree relatives of 549 probands who met the criteria for probable or definite AD and whose ApoE genotypes were known. ApoE genotypes for relatives were not determined. After age 65 the risk among relatives was proportional, as much as 7 to 10% at age 85, to the number of ~4 alleles present in the proband. Risks to relatives of ApoE 212 and 2/3 probands were nearly identical at all ages to risks for relatives of ApoE 3 / 3 probands. The expected proportion of relatives having at least one € 4 allele was calculated for each genotype group based on the distribution of parents, sibs, and offspring in the sample. Among relatives in the ApoE 3 / 3 group, the lifetime risk for AD by age 90 was three times greater than the expected proportion of ~4 carriers, suggesting that factors other than ApoE contribute to AD susceptibility. Furthermore, the 44% risk of AD by age 93 among relatives of ApoE 414 probands indicates that as many as 50(%' of people having at least one ~4 allele do not develop AD. We also found that among male relatives, risk of AD in the ApoE 314 group was similar to that for the ApoE 313 group but significantly less than the risk for the ApoE 414 group. In contrast, among female relatives the risk for the ApoE 314 group was nearly twice that for the ApoE 3 / 3 group and identical to the risk for the ApoE 414 group. These findings are consistent with a sex-modification effect of the E4 isoform on disease susceptibility. 
of these, the chromosome 2 I gene encoding P-amyloid precursor protein, the AD3 gene on chromosome 14, and the SMT2 gene on chromosome 1, account for a relatively small group of patients with autosomal dominantly transmitted disease that manifests usually before the age of 65 . The e 2 and e4 alleles of the apolipoprotein E (ApoE) gene are in linkage disequilibrium with A D in patients from various parts of the world with early onset [S] and late onset [9] of symptoms (see [ l o } for an extensive list of studies). The biological basis for these associations is unknown.
In vitro experiments suggest that the E3 (and E2) isoforms interact metabolically with microtubuleassociated proteins in a manner different from the E4 isoform Ell, 12). However, because neurons do not express ApoE messenger R N A (mRNA) and the cellular trafficking of ApoE in neurons is poorly understood, this explanation for the role of ApoE in A D pathogenesis is still speculative. Alternatively, aberrant interaction between ApoE and f3-amyloid may be a critical step in the disease [ 
131.
In spite of the compelling evidence for a dose effect of e4 on risk and age at onset of A D [ 141, the sensitivity and specificity of the association are modest 11 51.
Here, sensitivity refers to the proportion of individuals with e4 among those who will develop AD; specificity refers to the proportion of individuals without e4 among those who will not develop disease. Reduced sensitivity of ~4 for A D suggests that the disorder in many persons is caused by factors independent of ApoE. The observation that not all persons who have the ~4 allele develop A D (i.e., reduced specificity) suggests that either the effect of € 4 is modulated by other risk factors or such persons in whom the disease is apparently nonpenetrant have not survived to their eventual onset age.
To address the questions of sensitivity and specihcity of ApoE on risk of AD, we investigated the relationship between lifetime risk of disease, ApoE genotype, and sex in a group of 549 families in which the probands met rigorous diagnostic criteria and were genotyped for ApoE.
Materials and Methods

Su6jectnh
Two patient cohorts were recruited for this study. One group includes 378 participants in the Multi-Institutional Research in Alzheimer Genetic Epidemiology (MIRAGE) Study. M1-RAGE centers are tertiary care units that evaluate patients referred for a memory disorder. The groups participating in this study are the Alzheimer's Disease Resource MIRAGE patients were consecutively ascertained from the clinic populations at each of the centers and underwent a rigorous diagnostic evaluation including a neurological examination and appropriate neuropsychological, laboratory, and brain imaging tests. Eligible probands had a rating of 1 (59 subjects) or 2 (319 subjects) on the A axis of the MI-RAGE AD rating scale 1161. These ratings correspond to National Institute of Neurological anJ Communicative Disorders and Stroke/ Alzheimer's Disease and Related Disorders Association (NINCDSIADRDA) criteria for definite (i.e., autopsy-confirmed) or probable AD, respectively [ 171.
Interrater reliability of diagnosis among MIRAGE sites using this rating scale was found t o be sufficiently high 1161. Information on family history of dementia among first-degree relatives (i.e., parents, siblings, and children) was collected from a primary informant (usually a spouse or child, and occasionally a sibling) using standardized questionnaire instruments administered by direct or telephone interview. Multiple informants were sought to supplement and verify these responses. Relatives were considered t o be affected if they met criteria for ratings 1 to 4 on the MIRAGE AD rating scale.
Ratings of 3 or 4 correspond to varying degrees of certainty in the diagnosis of possible AD. Additional details regarding patient sampling and evaluation can be found elsewhere tV. S. Rao and colleagues, unpublished manuscript, 1995). Of the 1,150 probable and definite AD patients at these centers for whom family history information was available, tissue samples for D N A analysis were obtained for 59 autopsied subjects and 319 subjects who were evaluated in the clinic between July 1993 and April 1905. Selected characteristics of the probands are given in Table 1 .
The second subjecr group was composed of 171 patients enrolled in a population-based study in the Netherlands [ 181. All of these patients had onset of symptoms before the age of 65 years and are thus considered t o have early-onset AD.
Details of the study design and diagnostic criteria have been published [ l X , 191 . Probands were evaluated by two physicians who independently confirmed the diagnosis of probable AD using a standard protocol similar to NINCDSiADRDA and MIRAGE criteria. Our previous studies showed that lifetime risk and patterns of familial aggregation of illness among first-degree relatives of these patients [ 181 were similar to results obtained from studies of MGH patients [20, 211. 
ApoE Ge~otypiiig
The ApoE assay for the AD cases was performed by polymerase chain reaction (PCR) applying the methoJ of Wenharn and coworkers [221 or van Duijn and colleagues [ 8 ] . The ApoE gene was amplified using conditions as described elsewhere [8, 
Estimation of Lifetime Risk and Age at Onset Distribution
The lifetime risk of dementia and the age at onset distribution for first-degree relatives of the A D probands were estimated using a maximum likelihood procedure [25] . This method considers not only affected persons with known onset ages and unaffected persons with known censoring ages (i.e., those persons typically included in a Kaplan-Meier survival analysis [26] ), but also persons for whom onset age or censoring age data are missing. In this study. 35 affected and 75 unaffected individuals (2.75%) of all relatives) were lacking these data but were able to be incorporated in the analysis. This method also allows for the possibilities that a proportion of relatives asymptomatic at the time of study may be susceptible and express the disease later in life and that some dead relatives may have died from causes unrelated to AD although symptoms may have developed had they survived. All lifetime risks, mean ages at onset, and survival distributions reported here were estimated using this method. Parameter estimates and their standard errors for the estimated lifetime risk and mean onset age were compared between subgroups of A D relatives at the oldest age common to both groups. Since asymptotically these maximum likelihood statistics have normal distributions, a large sample Z statistic was used for these comparisons [27J Test-based confidence intervals for risk ratios were computed using this Z statistic. A log-rank statistic was used to test homogeneity of onset age distributions [28) . For the purpose of these analyses, probands were stratified by ApoE genotype. For some analyses, families of probands with an ApoE genotype of 212 or 213 were combined with families whose probands were 313, and families of probands with 214 were combined with 314 families. Gender effects were evaluated by further stratification of the relatives by sex and sex of the proband. Interaction of ApoE genotype and sex on lifetime risk of A D was tested formally by proportional hazard regression analysis in the 77.25% of subjects who had known censoring ages [29] . Models were evaluated using the PHREG procedure of the SAS ~301.
Distribution of ~4 among First-Degree Relatises
To assess directly the proportion of the estimated lifetime risk of disease among relatives attributable to ApoE genotype, one would need to have ApoE information on the relatives. This was not feasible because most parents and sibs are either deceased or otherwise unavailable for study. Genotyping children for ApoE is not warranted since most are too young to have expressed disease. However, the expected proportions of first-degree relatives of AD patients having at least one ApoE e4 allele can be derived from the conditional probabilities of the possible mating types among parents and spouses of the probands having a specified ApoE genotype. For these analyses, we modeled ApoE genotype as a twoallele system with frequencies p and q for the non-e4 (i.e., .52 and 83) and e4 alleles, respectively, and assumed that the frequency of the e4 allele in parental chromosomes not inherited by the proband was 0.135, that is, the same as in the general population t31). Because the 82 allele accounts for less than 8% of the polymorphism in the general population [31), its frequency was combined with that for e3. Hardy-Weinberg equilibrium among the allele frequencies was assumed.
To calculate the proportion of a specific group of relatives (ix., parents, sibs, or offspring) having the ApoE 314 or 414 genotype, the conditional probability of each possible mating type was multiplied by the proportion of relatives having the genotype, and these products were summed over all possible matings. The expected proportions of parents, sibs, and offspring having ApoE 314 and 414 genotypes are given in Table  2 . The expected proportion of first-degree relatives having at least one e4 allele was then determined in a two-step process. First, within each proband genotype group the expected frequencies from Table 2 for each set of relatives were summed to calculate the total proportion of individuals having at least one e4 allele. Second, these proportions were adjusted for the relative frequencies of parents, sibs, and offspring in the sample.
Results
Over a life span of 76 years, the risk for dementia to first-degree relatives of all AD probands was 40.6 + 4.3% (Table 3 ). The estimated mean onset age for affected relatives was 80. (Fig 1) .
T h e relative risk for A D by the age of 9.3 for those with an affcctcd relative with ~4 compared with those with an affected relative lacking ~4 is 1.65 t%".i con-
-2.4).
At every age after 65 years, the risk of A D among relatives was proportional t o the number of e 4 alleles present in the proband (Fig 2 ) Table 2 ) and the observed distribution of relatives were used to derive the expected proportion of relatives having at least one ~4 allele ( Approximately two thirds of the probands in this study were ascertained from specialty clinics for memory disorders participating in the MIRAGE Study and these subjects may not be representative of all AD patients. Clinic patients tend to have younger ages at onset and be more educated than others. Although age at onset may be related to ApoE genotype, it is unlikely that either of these factors distorted the association between ApoE genotype of the proband, familial clustering of AD, and gender. It is also possible that clinic patients are more likely to report a family history of dementia [32] . However, at age 70 the lifetime risk of A D in the relatives of MIRAGE patients (30.9 ? 2.5c/r) was less than the corresponding risk to relatives of the Dutch population-based patients (38.8 ? 6.29ii), but the difference was not significant ( p = 0.24). Another concern is that only one third of the MIRAGE patients at these centers were genotypcd for ApoE. Although most of the remaining subjects were either deceased or no longer followed in the clinic, refusal of some to donate a blood sample may have introduced a selection bias associated with perceptions of family history of AD. This is also unlikely because the 30.9% risk for relatives of the 378 MIRAGE patients in this study is nearly identical to the corresponding risk estimated for relatives of the total sample of 1,694 MIRAGE patients (32.9 2 1.3%) [33] .
The observations that relatives of ApoE 3/3 probands have a 38% lifetime risk (to age 96) of developing AD, but only 13% of these individuals are predicted to have at least one ~4 allele, suggest that familial factors (genetic or nongenetic) independent of ApoE contribute substantially to disease susceptibility. van Duijn and coauthors [8} reported that both the number of ~4 alleles and a family history of a first- Alternatively, a much larger sample of e 2 probands may be needed to demonstrate a difference in lifetime risk of A D among relatives. It is also plausible that the effect of ~2 on risk of AD may depend on other genetic or environmental factors. Our study sample includes patients from various ethnic backgrounds and geographic regions.
The trend of younger onset age among affected relatives with dose of e4 in the proband was nor significant.
In fact, because in our procedure mean onset age was estimated simultaneously with the lifetime risk, the means would have been even more similar had the maximum onset ages for each group been the same. Lack of a dose effect reflects, perhaps, a limitation of our study design for relating ApoE genotype in probands to risk of illness and expression in relatives. Rather, our results suggest the presence of a sexmodification effect of the ApoE 4 isoform on disease susceptibility. Among women, a single copy of the ~4 allele appears to be sufficient to elevate disease risk from baseline (i.e., risk of disease among persons having the ApoE 3 / 3 genotype), whereas among men, a double dose of € 4 is necessary to attain the same increase in risk. This hypothesis is supported by our findings from segregation analysis which suggest that after adjusting for gender differences in longevity, women are innately more susceptible than men to AD [60] . Factors that may be specific to women, or act differently in women than men, and modify the deleterious effects of ApoE 4 include hormones such as estrogen [61] , antiinflammatory drugs [62) , and cholesterol [36f. Studies of the interaction of these factors with ApoE may provide important clues for preventing onset of the disorder.
Our findings have important clinical implications. An individual may have an affected parent or sibling who is diagnosed with AD and wishes to know his or her risk based on the ApoE genotype of the affected family member. On the basis of data reported by Corder and associates [43] , the sensitivity for diagnosing AD from the detection of two ~4 alleles is 6957 and the specificity is 72%' [lS]. Our results suggest that the predictive value of ApoE genotype could be improved by incorporating information on the consultant's sex and residual genetic factors. Until tests for other genetic factors for AD are developed (amyloid precursor protein [APP} mutations and defects in chromosomes 1-and 14-linked genes are apparently rare causes of AD), one could incorporate a quantitative assessment of the person's family history [63] into the diagnostic test. 
